The investigational cancer vaccine, NOUS-209, was found to safely stimulate the immune system to target precancerous and cancerous cells in individuals with Lynch Syndrome (LS). The results of a Phase Ib/II clinical trial, led by Eduardo Vilar-Sanchez, M.D., Ph.D., chair ad interim of Clinical Cancer Prevention, provide early evidence that immune-based approaches, such as NOUS-209, may be able to intercept cancer before it develops, offering a potential new avenue for preventive care for high-risk individuals.
“Current management strategies for Lynch Syndrome patients – frequent screenings or elective preventive surgery – are life-changing interventions that help prevent cancer development but can significantly affect quality of life,” Vilar-Sanchez said. “By teaching the immune system to recognize and attack abnormal cells, this therapy offers a promising new approach to this patient population, who face a significantly higher risk of colorectal, endometrial, urothelial, and other cancers.”